^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BMS-986179

i
Other names: BMS-986179, BMS 986179, BMS986179
Associations
Trials
Company:
BMS
Drug class:
CD73 inhibitor
Associations
Trials
almost4years
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov)
P1/2, N=268, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Nov 2020 --> Feb 2023
Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CD73 (5'-Nucleotidase Ecto)
|
CD73 expression
|
Opdivo (nivolumab) • BMS-986179